AVITA director receives RSU and option grants
AVITA Medical, Inc. director Suzanne Crowe reported equity awards granted as part of her compensation.
Rhea-AI Filing Summary
AVITA Medical, Inc. director Suzanne Crowe reported equity awards granted as part of her compensation. She received 22,214 restricted stock units, each representing one share of common stock, which vest 12 months after the January 20, 2026 grant date, subject to previously obtained stockholder approval. She was also granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share, exercisable until January 20, 2036. Following these awards, her direct holdings total 69,148 shares of common stock, which include unvested RSUs and 22,990 CHESS Depositary Interests that translate into 4,598 of these shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 38,347 shares
Grant/Award
2 txns
Insider
Crowe Suzanne
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 16,133 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 22,214 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (Right to Buy) — 16,133 contracts (Direct);
Common Stock — 69,148 shares (Direct)
Footnotes (4)
- F1. Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- F2. Includes unvested RSUs.
- F3. Includes 22,990 of the Issuer's CDIs. The Reporting Person's 22,990 CDIs translate into 4,598 of the shares of Common Stock set forth above.
- F4. On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
Key Figures
RSU grant: 22,214 units
Option grant size: 16,133 options
Option exercise price: $3.77/share
+4 more
7 metrics
RSU grant
22,214 units
Restricted stock units granted January 20, 2026, vesting after 12 months
Option grant size
16,133 options
Options to acquire common stock granted to non-executive director
Option exercise price
$3.77/share
Exercise price equals Nasdaq closing price on January 20, 2026
Total holdings after grants
69,148 shares
Direct common stock holdings following reported transactions
CDIs held
22,990 CDIs
Translate into 4,598 of the common shares in total holdings
Option expiration
January 20, 2036
Expiration date of 16,133 stock options
RSU vesting
12 months post-grant
RSUs vest 12 months after January 20, 2026 grant date
Key Terms
restricted stock units, RSUs, CHESS Depositary Interests, stock options, +1 more
5 terms
restricted stock units financial
"Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right..."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right..."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
CHESS Depositary Interests financial
"Includes 22,990 of the Issuer's CDIs. The Reporting Person's 22,990 CDIs translate into 4,598..."
CHESS depositary interests are tradable certificates used on the Australian settlement system that represent ownership of underlying foreign shares held by a custodian. They let investors buy and sell foreign-listed stocks on the local exchange as if they were domestic shares, simplifying trading, dividend collection and record-keeping, though they may involve custodian fees and can alter certain direct shareholder rights and tax treatments.
stock options financial
"On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares..."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"with a grant date of January 20, 2026 and an exercise price equal to the closing price..."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did AVITA Medical (RCEL) director Suzanne Crowe report?
Suzanne Crowe reported awards of 22,214 restricted stock units and 16,133 stock options in AVITA Medical common stock. These are compensation-related grants, not open-market purchases or sales, and increase her equity-based exposure to the company.
What are the terms of Suzanne Crowe’s restricted stock units in AVITA Medical (RCEL)?
Crowe received 22,214 restricted stock units, each equal to one AVITA common share. The RSUs are subject to time-based vesting and vest on the date 12 months after the January 20, 2026 grant date, following stockholder approval obtained June 3, 2026.
What are the key details of the stock options granted to Suzanne Crowe by AVITA Medical (RCEL)?
Crowe received 16,133 stock options to acquire 16,133 AVITA common shares at an exercise price of $3.77 per share. The options were granted January 20, 2026 to non-executive directors and are exercisable until their expiration on January 20, 2036.
How were Suzanne Crowe’s AVITA Medical (RCEL) option grants determined?
On January 5, 2026, AVITA’s board approved grants of 16,133 options to each non-executive director. The options have a grant date of January 20, 2026 and an exercise price set at the Nasdaq closing price that day, disclosed as $3.77 per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
